Neurotechnologies are based on the principles of the human nervous system and modeled on the human brain. NeuroTech can help researchers understand brain function and disfunction, and can help doctors treat neurological disorders. Some NeuroTech applications are focused on enhancing cognitive performance, improving sleep, and improving brain health for Longevity. Advances in AI could revolutionize NeuroTech over the next decade. NeuroTech has unprecedented prospects for growth both in terms of technology and as an industry.

Over the past 100 years the financial industry has largely excluded people in retirement. Even today tech entrepreneurs are ignoring financial inclusion for people over 60, who make up the wealthiest part of the financial system, and instead, are developing financial products for younger people. The most valuable and capable client demographic in terms of purchasing power are the citizens of the 7th Continent which is made up of 1 billion people over 60. The global spending power of this demographic is expected to be $15 trillion this year. Who will serve this market?

AI for Longevity has more potential to increase healthy Longevity in the short term than any other sector. The application of AI for Longevity will bring the greatest real-world benefits and will be the main driver of progress in the widespread extension of healthy Longevity. The global spending power of people aged 60 and over is anticipated to reach $15 trillion annually by 2020. The Longevity industry will dwarf all other industries in both size and market capitalization, reshape the global financial system, and disrupt the business models of pension funds, insurance companies, investment banks, and entire national economies. Longevity has become a recurring topic in analytical reports from leading financial institutions such as CitiBank, UBS Group, Julius Baer, and Barclays.

AI for Longevity has more potential to increase healthy Longevity in the short term than any other sector. The application of AI for Longevity will bring the greatest real-world benefits and will be the main driver of progress in the widespread extension of healthy Longevity. The global spending power of people aged 60 and over is anticipated to reach $15 trillion annually by 2020. The Longevity industry will dwarf all other industries in both size and market capitalization, reshape the global financial system, and disrupt the business models of pension funds, insurance companies, investment banks, and entire national economies. Longevity has become a recurring topic in analytical reports from leading financial institutions such as CitiBank, UBS Group, Julius Baer, and Barclays.

AI for Longevity has more potential to increase healthy Longevity in the short term than any other sector. The application of AI for Longevity will bring the greatest real-world benefits and will be the main driver of progress in the widespread extension of healthy Longevity. The global spending power of people aged 60 and over is anticipated to reach $15 trillion annually by 2020. The Longevity industry will dwarf all other industries in both size and market capitalization, reshape the global financial system, and disrupt the business models of pension funds, insurance companies, investment banks, and entire national economies. Longevity has become a recurring topic in analytical reports from leading financial institutions such as CitiBank, UBS Group, Julius Baer, and Barclays.

There's been significant growth in the AI for Drug Discovery sector this year. In the last quarter, the number of R&D centers increased by 5, companies increased by 20, collaborations increased by 30, and investors increased by 50. There are now 400 investors investing in AI for Drug Discovery including Google Ventures, Tencent, WuXi, Andreessen Horowitz, Khosla Ventures, and Sequoia Ventures. This week, Deep Knowledge Analytics Pharma Division published Landscape of AI for Drug Discovery and Advanced R&D Q2 2019. This report is the most comprehensive analytical report on the AI for Drug Discovery sector to date.

In our new book Longevity Industry 1.0 - Defining the Biggest and Most Complex Industry in Human History, Dmitry Kaminskiy and I distill the complex assembly of deep market intelligence and industry knowledge that we have developed over the past five years. We present the full-scope of the Global Longevity Industry showing exactly how we managed to define this complex and multidimensional industry and how we created a tangible framework for systematization and forecasting. This article includes the preface and the foreword from our book. Every cause of death is, in principle, preventable. I became aware of this in the 1990s and since then I have been following aging research very closely.